130 related articles for article (PubMed ID: 37811793)
1. Cost-Effectiveness Analysis for Therapy Sequence in Advanced Cancer: A Microsimulation Approach with Application to Metastatic Prostate Cancer.
Handorf EA; Beck JR; Correa A; Ramamurthy C; Geynisman DM
Med Decis Making; 2023; 43(7-8):949-960. PubMed ID: 37811793
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer.
Ramamurthy C; Handorf EA; Correa AF; Beck JR; Geynisman DM
Urol Oncol; 2019 Oct; 37(10):688-695. PubMed ID: 31399302
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective.
Chiang CL; So TH; Lam TC; Choi HCW
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):108-115. PubMed ID: 31273290
[TBL] [Abstract][Full Text] [Related]
4. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
Sathianathen NJ; Alarid-Escudero F; Kuntz KM; Lawrentschuk N; Bolton DM; Murphy DG; Kim SP; Konety BR
Eur Urol Oncol; 2019 Nov; 2(6):649-655. PubMed ID: 31411985
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
Barqawi YK; Borrego ME; Roberts MH; Abraham I
J Med Econ; 2019 Nov; 22(11):1202-1209. PubMed ID: 31452414
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer.
Lester-Coll NH; Ades S; Yu JB; Atherly A; Wallace HJ; Sprague BL
JAMA Netw Open; 2021 Jan; 4(1):e2033787. PubMed ID: 33439266
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model.
Hird AE; Magee DE; Cheung DC; Matta R; Kulkarni GS; Nam RK
Can Urol Assoc J; 2020 Sep; 14(9):E418-E427. PubMed ID: 32223875
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
Yoo M; Nelson RE; Haaland B; Dougherty M; Cutshall ZA; Kohli R; Beckstead R; Kohli M
J Natl Cancer Inst; 2023 Nov; 115(11):1374-1382. PubMed ID: 37436697
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.
Wang L; Hong H; Alexander GC; Brawley OW; Paller CJ; Ballreich J
Value Health; 2022 May; 25(5):796-802. PubMed ID: 35500949
[TBL] [Abstract][Full Text] [Related]
10. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
Parikh NR; Chang EM; Nickols NG; Rettig MB; Raldow AC; Steinberg ML; Koontz BF; Vapiwala N; Deville C; Feng FY; Spratt DE; Reiter RE; Phillips R; Ost P; Tran PT; Kishan AU
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):917-926. PubMed ID: 32544574
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan.
Okumura H; Inoue S; Naidoo S; Holmstrom S; Akaza H
Jpn J Clin Oncol; 2021 Aug; 51(8):1319-1329. PubMed ID: 34037235
[TBL] [Abstract][Full Text] [Related]
13. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
14. Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.
Barbier MC; Tomonaga Y; Menges D; Yebyo HG; Haile SR; Puhan MA; Schwenkglenks M
PLoS One; 2022; 17(11):e0277282. PubMed ID: 36327294
[TBL] [Abstract][Full Text] [Related]
15. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Woods BS; Sideris E; Sydes MR; Gannon MR; Parmar MKB; Alzouebi M; Attard G; Birtle AJ; Brock S; Cathomas R; Chakraborti PR; Cook A; Cross WR; Dearnaley DP; Gale J; Gibbs S; Graham JD; Hughes R; Jones RJ; Laing R; Mason MD; Matheson D; McLaren DB; Millman R; O'Sullivan JM; Parikh O; Parker CC; Peedell C; Protheroe A; Ritchie AWS; Robinson A; Russell JM; Simms MS; Srihari NN; Srinivasan R; Staffurth JN; Sundar S; Thalmann GN; Tolan S; Tran ATH; Tsang D; Wagstaff J; James ND; Sculpher MJ
Eur Urol Oncol; 2018 Dec; 1(6):449-458. PubMed ID: 31158087
[TBL] [Abstract][Full Text] [Related]
16. Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.
Reddy D; van Son M; Peters M; Bertoncelli Tanaka M; Dudderidge T; Cullen E; Ho CLT; Hindley RG; Emara A; McCracken S; Orczyk C; Shergill I; Mangar S; Nigam R; Virdi J; Moore CM; Arya M; Shah TT; Winkler M; Emberton M; Falconer A; Belsey J; Ahmed HU
J Med Econ; 2023; 26(1):1099-1107. PubMed ID: 37656223
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer.
Pelloux-Prayer R; Schiele P; Oudard S; Gravis G; Kleinclauss F; Crehange G; Hennequin C; Morgans AK; Geoffrois L; Limat S; Thiery-Vuillemin A; Nerich V
Clin Genitourin Cancer; 2021 Oct; 19(5):e326-e333. PubMed ID: 33962909
[TBL] [Abstract][Full Text] [Related]
18. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.
Zhong L; Pon V; Srinivas S; Nguyen N; Frear M; Kwon S; Gong C; Malmstrom R; Wilson L
PLoS One; 2013; 8(5):e64275. PubMed ID: 23717582
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
Zheng HR; Wen F; Wu YF; Wheeler JRC; Li Q
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27145493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]